Liquidia Corporation Reports Full Year 2023 Financial Result

Preparing to launch YUTREPIA™ inhalation powder upon final FDA approvalFederal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent...

Related Keywords

United States , Delaware , America , Pharmosa Biopharm , Jason Adair , Roger Jeffs , United Therapeutics Corporation , Drug Administration , Us District Court , Company Contacts , Us Court , Liquidia Technologies Inc , Liquidia Corporation , Sandoz Inc , York Heart Association , Silicon Valley Bank , United Therapeutics , Chief Executive Officer , Patent Trial , Appeal Board , Federal Circuit , United Therapeutic , Judge Andrews , Patient Square Capital , Healthcare Royalty Partners , Revenue Interest Financing Agreement , Treprostinil Injection , Promotion Agreement , North America , Restated Loan , Security Agreement , New York Heart Association , Functional Class , New Drug Application , Dry Powder Inhalation , Abbreviated New Drug Application , Liquidia Technologies , Private Securities Litigation Reform Act , Ended December , Markets ,